Last reviewed · How we verify
Cannabidiol , synthetic form
At a glance
| Generic name | Cannabidiol , synthetic form |
|---|---|
| Sponsor | Stero Biotechs Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial (PHASE3)
- Role of CBD in Improving Alexithymia (PHASE2)
- A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients (PHASE2)
- Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cannabidiol , synthetic form CI brief — competitive landscape report
- Cannabidiol , synthetic form updates RSS · CI watch RSS
- Stero Biotechs Ltd. portfolio CI